| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2017 , Vol 55 , Num 3
The Effects of Some Imidazopyrazine Derivatives on Telomerase Inhibition, mtDNA Damage and mtDNA Copy Number
1 Mehmet Akif Ersoy University, Arts and Sciences Faculty, Department of Molecular Biology and Genetics, Burdur, Turkey2 Mehmet Akif Ersoy University, Arts and Sciences Faculty, Department of Biology, Burdur, Turkey
3 Mehmet Akif Ersoy University, Arts and Sciences Faculty, Department of Chemistry, Burdur, Turkey
4 Mehmet Akif Ersoy University, Arts and Sciences Faculty, Department of Physics, Burdur, Turkey
5 Medipol University, Faculty of Pharmacy, İstanbul, Turkey
DOI : 10.23893/1307-2080.APS.05517 Viewed : 18740 - Downloaded : 6249 Imidazopyrazine derivatives have been studied for their curative effects on some diseases like cancer and neurological problems; also, some of these molecules have been patented. Primary human cells exhibit limited replicative potential but the cancer cells divided unlimitedly with passage in culture. This immortality is mainly a result of telomerase activity. We investigated the possible telomerase inhibitor effect and possible mtDNA damage action of five imidazopyrazine derivatives. Telomerase activities were measured by the PCR-ELISA based TRAP method and mtDNA damage assays were achieved by quantitative PCR. We used zebrafish as a model organism for our research. In the application of 6-(4-Metylphenyl-8-(4- chlorophenyl)imidazo[1,2-a]pyrazine (C19H14N3Cl), it was determined that this compound inhibit telomerase activities to a statistically significant degree. The obtained results from molecular docking studies also supported the experimental results. Accordingly, this compound has the probability to be used as an anti-cancer agent after detailed studies. Keywords : Imidazopyrazine derivatives, Telomerase inhibition, mtDNA damage, mtDNA copy number, anticancer drugs
